ArticleAmerican journal of translational research2026
Modular FRET sensor for site-specific detection of protein arginine methylation in living cells.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate a modular fluorescence resonance energy transfer (FRET) biosensor for site-specific real-time detection of protein arginine methylation and to explore its translational relevance using a synthetic oncology cohort.
methodsA synthetic cohort of 200 patients with breast, colorectal, and lung cancer was generated to reflect real-world demographics and clinical distribution. A modular FRET biosensor (composed of donor-receptor fluorophores linked by a methylarginine recognition domain) was used to quantify the methylation index of different tumor subgroups.
resultsThe FRET biosensor demonstrated superior diagnostic accuracy in identifying tumors with high methylation burden. The definition of high methylation burden was based on a clinically informed threshold (≥0.65) optimized using receiver operating characteristic (ROC) and was supported by survival relevance. Patients with elevated FRET-derived methylation indices showed significantly shorter progression-free survival (8.9 months vs. 14.6 months; hazard ratio (HR) 1.92, 95% confidence interval (CI) 1.41-2.63, P<0.001) and overall survival (OS) (21.4 months vs. 36.2 months; HR 2.11, 95% confidence interval (CI) 1.55-2.87, P<0.001). In the hypermethylation subgroup, the addition of a protein arginine methyltransferase inhibitor was associated with a higher objective response rate (38% vs. 21%, P=0.008), but showed no significant trend towards improved survival.
conclusionThis study demonstrates the potential translational application value of modular FRET biosensors in the dynamic monitoring of protein arginine methylation. Although the study was based on a synthetic cohort, the results highlight the potential of FRET-based methylation sensing technology as a research and biomarker development tool, and warrant validation in future real-world clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.